BCLI.US Brainstorm Cell Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.9900 USD
Close of Nov 13, 2026
0.4600 1.69
Market cap
USD 10.9M
P/E
-
P/B
54.50x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BCLI.US undervalued?

Graham number

The Graham number of Brainstorm Cell Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Brainstorm Cell Therapeutics Inc fundamental analysis

No fundamental analysis for Brainstorm Cell Therapeutics Inc yet.

Brainstorm Cell Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal …

Full company profile